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Abstract
Introduction: Aggressive pituitary tumours causing Cushing’s Disease are very rare, difficult to treat, and usually resistant to conventional 
therapy. There is growing evidence for the use of temozolomide (TZM), an alkylating chemotherapeutic agent, as first-line chemotherapy 
in such tumours.
Objective: To present the response to TMZ in an aggressive pituitary tumour and Cushing’s Disease and to review the literature refer-
ring to similar cases.
Case report: A sixty-one-year-old male patient was diagnosed with Cushing’s Disease and invasive macroadenoma in 2011. Four trans-
sphenoidal non-radical neurosurgeries (2012, 2013) with rapid tumour progression, repeated non-radical bilateral adrenalectomy (2012, 
2013) and stereotactic radiotherapy, and gamma knife surgery (2013, 2015) were performed. Histopathological examination revealed 
macroadenoma with high cell polymorphism and the presence of Crooke’s cells, Ki- < 2%. Since 2015 the patient has been treated with 
six cycles of TMZ with clinical and biochemical improvement and stabilised tumour size and no side effects. TMZ was continued for up 
to nine cycles; however, symptoms like headaches, visual field impairment, and hearing loss were progressing. After the ninth cycle of 
TMZ, there was a sudden increase in the size of the tumour with deterioration of the clinical status. The patient died in February 2016. 
Conclusions: The case of our patient suggests that the response to the TMZ treatment monotherapy in an aggressive pituitary tumour 
causing Cushing’s Disease could be partial, followed by rapid progression of the tumour mass. Further research should be carried out to 
investigate predictors of responsiveness and to extend duration of TMZ treatment. (Endokrynol Pol 2018; 69 (3): 306–312)
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Streszczenie
Wstęp: Agresywne guzy przysadki powodujące chorobę Cushinga występują bardzo rzadko, są trudne do leczenia i zazwyczaj oporne 
na terapię konwencjonalną. Istnieje coraz więcej dowodów na zastosowanie temozolomidu (TZM), alkilującego środka chemioterapeu-
tycznego, jako chemioterapii pierwszej linii w tego rodzaju guzach.
Cel: Zaprezentowanie odpowiedzi na leczenie TMZ w przypadku agresywnego guza przysadki i choroby Cushinga oraz przegląd pi-
śmiennictwa odnoszącego się do podobnych przypadków.
Opis przypadku: Mężczyzna w wieku 61 lat, ze zdiagnozowaną od 2011 roku chorobą Cushinga i inwazyjnym makrogruczolakiem. Prze-
prowadzono następujące zabiegi: cztery transsfenoidalne nieradykalne zabiegi neurochirurgiczne (2012, 2013 r.) z szybko postępującym 
guzem, powtarzaną nieradykalną obustronną adrenalektomię (2012, 2013 r.) oraz radioterapię stereotaktyczną i zabieg nożem gamma 
(2013, 2015 r.). Badanie histopatologiczne wykazało obecność makrogruczolaka z wysokim stopniem polimorfizmu komórkowego oraz 
obecność komórek Crooke’a, Ki- < 2%. Od 2015 roku pacjent przebył sześć cyklów leczenia TMZ z poprawą parametrów klinicznych 
i biochemicznych, z ustabilizowaną wielkością guza i brakiem efektów ubocznych. Leczenie TMZ kontynuowane było do dziewięciu 
cyklów, jednak objawy, takie jak bóle głowy, zaburzenia pola widzenia oraz utrata słuchu postępowały. Po zakończeniu dziewiątego 
cyklu leczenia TMZ nastąpił nagły wzrost wielkości guza razem z pogorszeniem stanu klinicznego. Pacjent zmarł w lutym 2016 roku.
Wnioski: Przykład opisywanego pacjenta może sugerować, że odpowiedź na monoterapię TMZ w przebiegu agresywnego guza przysadki 
powodującego chorobę Cushinga może być częściowa, z następującym później szybkim wzrostem masy guza. Wskazane jest prowadzenie 
dalszych badań, aby przeanalizować czynniki mające wpływ na odpowiedź oraz wydłużyć czas trwania leczenia TMZ. (Endokrynol Pol 
2018; 69 (3): 306–312)
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Abbreviations 
TMZ — temozolomide 
ACTH — adrenocorticotropic hormone 
PRL — prolactin 
TSH — thyroid-stimulating hormone 
FSH — follicle-stimulating hormone 
LH — luteinising hormone 
ESE — European Society of Endocrinology 
MGMT — O6-methyl-guanine-DNA methyltransferase 
MMMRI — magnetic resonance imaging 
CAPTEM — capecitabine and temozolomide 
PPRT — peptide receptor radionuclide therapy
PET-CT — positron emission tomography-computed 
tomography European Society of Endocrinology
Introduction
The prevalence of clinically relevant pituitary tumours 
is 80–100 cases per 100,000 with an annual incidence of 
one new case per 100,000 [1–3]. Some of the pituitary 
tumours could remain clinically silent for a long time as 
many grow slowly over several years. However, some 
pituitary tumours present as aggressive with rapid 
growth. They are usually invasive macroadenomas with 
a high recurrence rate, resistant to repeated treatments 
[1–4]. There is no clear definition of aggressive pituitary 
tumours. Therefore, the European Society of Endo-
crinology European Society of Endocrinology(ESE) is 
currently preparing guidelines for the diagnosis and 
management of aggressive pituitary tumours (www.
ese-hormones.org/). Also, little is known about the 
prevalence and treatment effectiveness of aggressive 
pituitary tumours causing Cushing’s Disease. The 
management of aggressive pituitary tumours is a mul-
tidisciplinary challenge to clinicians with neurosurgery 
as a first-line treatment followed by radiotherapy and 
pharmacotherapy. There is growing evidence for the 
use of temozolomide (TZM) monotherapy as first-line 
chemotherapy. In 2017 Halevy and Whitelaw published 
a review of the literature regarding the effectiveness of 
TMZ in pituitary tumour treatment [4]. 
Temozolomide (TMZ) is an alkylating cytostatic 
drug, used initially for the treatment of glioblastoma 
multiforme, but shown to be effective also in other 
central nervous system neoplasms. Recently it has been 
used in the treatment of aggressive pituitary adenomas. 
Temozolomide causes DNA damage through methyla-
tion of the O6 position of guanine, creating the cytotoxic 
DNA adducts, apoptosis of target cells, and cell necrosis, 
and consequently decreases tumour volume [5–8]. 
Aggressive pituitary tumours secreting ACTH are 
a rare type of corticotropinoma, which demonstrate 
invasive growth, high recurrence rate, and are resistant 
to conventional therapy [7]. Less than 1% of all pituitary 
adenomas are built with Crooke’s cells and only about 
4.4–14% of corticotropinomas contain Crooke’s cells. To 
date, there are only about 80 described cases of Crooke’s 
cell adenoma [9, 10].
Case presentation 
We present a case of a patient with ACTH-dependent 
Cushing’s syndrome caused by Crooke’s cell cortico-
tropinoma. A 61-year-old male patient was referred to 
our clinic in December 2011. During the first hospitali-
sation the patient presented with signs and symptoms 
of severe hypercorticoidism and an excess ACTH level 
(abdominal obesity, moon face, hyperpigmentation of 
the skin, supraclavicular fat and dorsocervical fat pads 
[buffalo hump], purple striae, easy bruising, depression, 
swelling of feet, diabetes mellitus, hypertension). The 
patient suffered from advanced heart failure, severe 
headaches, and progressing visual field impairment. 
Progressing symptoms of the disease were present for 
2–3 years before diagnosis. We observed advanced os-
teoporosis in the DEXA scan examination and a fracture 
of the Th5 vertebra in the X-ray examination. In 2011 
the patient also underwent a neurosurgical intervention 
of the spine (L5-S1). 
Upon admission, the laboratory tests revealed: 
morning ACTH level — 192.6 pg/mL, mean serum 
cortisol level 30.81 μg/d, and a lack of suppression 
serum cortisol after the administration of two-day low- 
and high-dose dexamethasone. Magnetic resonance 
imaging (MRI) showed a 33 × 29 × 26-mm mass with 
suprasellar extension, right cavernous sinus invasion, 
and a moved right carotid artery. The tumour mass 
elevated the optic chiasm. The abdominal ultrasound 
was non-significant. The patient was referred to the 
Department of Neurosurgery, where transsphenoidal 
surgery was performed (January 2012). Histopatho-
logical examination revealed a macroadenoma with 
high cell polymorphism and the presence of Crooke’s 
cells, Ki-67 < 2%; immunohistochemistry was positive 
for ACTH and negative for other pituitary hormones 
(growth hormone, PRL, TSH, FSH, LH). Due to refrac-
tory signs and symptoms of severe hypercorticoidism, 
in 2012 and 2013, the patient was qualified for bilateral 
adrenalectomy for life-saving indications with post-
operative fast recurrence of hypercorticoidism. Due 
to tumour regrowth, another three transsphenoidal 
non-radical neurosurgeries were performed (2012 
and 2013). Repeated stereotactic radiotherapy (Dc 
50.4 Gy and Dc 18 Gy, CyberKnife) was performed 
(August 2013 and April 2015) (Table I). From the time 
of diagnosis, the patient had been treated with ke-
toconazole (300 to 600 mg per day). The treatment 
was modified several times due to the exacerbation 
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of hypercorticoidism and the observed deterioration 
of liver function. 
The clinical status of the patient gradually worsened 
with the progression of severe cardiac insufficiency. 
The patient was not qualified for another gamma-knife 
surgery; the patient suffered from severe headaches 
and right oculomotor nerve paresis. Deterioration of 
the visual field was also observed. 
Based on the above, we decided to start treatment 
with temozolomide. The first course was initiated in 
April 2015. We administered a standard dose of TMZ, 
widely used for malignant glioma (150–200 mg/m2) once 
daily in the morning, for five consecutive days (28-day 
cycle). From the beginning of the diagnosis the patient 
was continuously treated with ketoconazole (average 
dose 600 mg). Since 2015 he was treated with six cycles 
of TMZ (320 mg per day for five consecutive days 
(28-day cycle). Clinical and biochemical improvement 
was observed. During the third cycle, morning cortisol 
and ACTH decreased by 17% and 40%, respectively, com-
pared to baseline measurement (April 2015) (Table II). 
The maximal decrease of morning cortisol and ACTH 
with clinical improvement was observed after the 
seventh cycle (decrease by 52% and 56%, respectively, 
compared to baseline measurement) (Table II, Figure 1). 
Clinical improvement manifested from the third cycle 
with less frequent and less severe headaches, improved 
right oculomotor nerve paresis, improvement of the 
visual field, and improved physical fitness and mood. 
Clinical and cardiographic improvement of heart insuf-
ficiency was also seen. In the control MRI (July 2015) 
the size of the tumour was the same as in the previous 
MRI examination (30 × 35 × 35 mm). We continued 
the treatment to the ninth cycle and observed a stable 
decrease and stabilisation in the level of cortisol and 
ACTH during the consecutive cycles. However, the 
clinical symptoms such as the headaches, visual field 
impairment, and finally hearing loss started to progress 
from the eighth cycle (December 2016). After the ninth 
cycle of TMZ, in December 2015, there was a sudden 
increase in the size of the tumour to 35 × 53 × 54 mm, 
while the cortisol and ACTH levels remained stable. The 
tumour reached the inner ear with visible compression 
on the cochlea. In February 2016, one month after dis-
continuation of TMZ, the cortisol serum level remained 
stable while ACTH increased by 28% when com-
pared to a measurement from January 2016 (Table II). 
After discontinuation of TMZ, we observed the pro-
gressing impairment of the patient’s clinical status with 
a sudden clinical status crisis: sight deterioration, strong 
headache, right oculomotor nerve paresis, and hearing 
loss. Progressive hearing loss was observed from the 
eighth/ninth cycle. We decided to start treatment with 
Pasireotide (0.6 mg s.c twice a day). After the imple-
mentation of the drug, a rapid deterioration of diabetes 
was observed. The patient died in February 2015. The 
most probable reason for death was compression of the 
brainstem, which had been observed in the last MRI of 
the pituitary (Figure 2 and 3). 
Haematological parameters, liver function tests, and 
careful clinical observation were performed periodical-
ly. To prevent possible side effects, the patient received 
Table II. Serum cortisol [μg/dL] and ACTH levels [pg/mL] 
measured before the TMZ cycle and after discontinuation of 
the treatment
Tabela II. Wartości stężenia kortyzolu w surowicy krwi 
[μg/dl] oraz stężenie ACTH [pg/ml], mierzone przed cyklem 
leczenia TMZ
DATE Before 
cycle
Serum cortisol level  
[μg/dL]*
ACTH  
[pg/mL]**
8 am 12 pm
24.04.2015 1st cycle 36.2 35.6 1317
27.05.2015 2nd cycle 29.4 19.53 1108
24.06.2015 3rd cycle 30 28 785
22.07.2015 4th cycle 39.1 35.8 1057
20.08.2015 5th cycle 30.95 27.2 840
17.09.2015 6th cycle 24.1 26.3 689
15.10.2015 7th cycle 17.3 19.91 572
16.11.2015 8th cycle 20.66 16.1 957
17.12.2015 9th cycle 29.4 25.61 779
14.01.2016 Post*** 22.03 22.58 769
05.02.2016 Post*** 21.02 16.22 1080
*serum cortisol normal range [2.30–23.30 μg/dL] 
**serum ACTH range [6.0–56.0 pg/mL] 
***measurements performed after temozolomide discontinuation
Table I. Chronology of the treatments implemented in the 
patient
Tabela I. Zabiegi przeprowadzone u pacjenta, w kolejności 
chronologicznej
The management Date
1st transsphenoidal Non-radical neurosurgery 05.01.2012
Non-radical left adrenalectomy 27.04.2012
Right adrenalectomy 21.05.2012
2nd transsphenoidal Non-radical neurosurgery 19.06.2012
3rd transsphenoidal Non-radical neurosurgery 08.10.2012
Left adrenalectomy 28.02.2013
4th transsphenoidal Non-radical neurosurgery 19.04.2013
Stereotactic radiotherapy 08.2013
Stereotactic radiotherapy 04.2015
9 cycles of temozolomide therapy 04–12. 2015
Pasireotide treatment 01–02.2016
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Figure 1 and 2. MRI of the pituitary, February 2016
Rycina 1, 2. MRI przysadki mózgowej, luty 2016
Figure 3. Serum cortisol levels during 9 cycles of temozolomide treatment and after treatment discontinuation
Rycina 3. Wartości stężenia kortyzolu w surowicy krwi podczas dziewięciu cyklów leczenia temozolomidem oraz po zaprzestaniu leczenia
Figure 2. ACTH [pg/mL] during temozolomide treatment and after treatment discontinuation
Rycina 2. Lortykotropina (ACTH) [pg/ml] podczas leczenia temozolomidem oraz po zaprzestaniu leczenia
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ondansetron and trimethoprim-sulfamethoxazole. 
Apart from mild nausea, we did not observe any com-
mon adverse effects during treatment. 
Discussion
In our case, a patient with an aggressive pituitary 
corticotroph tumour with severe clinical symptoms of 
Cushing’s Disease, resistant to repeated neurosurgery, 
bilateral adrenalectomy, and radiotherapy, improved 
after the implementation of TMZ. Serum cortisol and 
ACTH levels significantly decreased and were stable 
up to the ninth cycle, while the clinical progression of 
symptoms due to tumour mass effects were present 
from the eighth cycle. We did not observe any typical 
TMZ side effects, except for mild nausea and progres-
sive hearing loss from the eighth/ninth cycle. The treat-
ment was continued for nine cycles. During the ninth 
cycle sudden clinical deterioration and rapid tumour 
growth were observed. 
Similarly to our case, aggressive pituitary tumours 
usually respond badly to standard medical treatments. 
The first-line treatment of aggressive pituitary tumours 
is neurosurgery; however, in about 35% of patients we 
observe regrowth with median follow-up of regrowth 
by 5.9 years [11].
Radiotherapy is usually the third-line treatment. Un-
like repeated operations that can be considered in suit-
able patients, radiation treatment is limited by the risk 
of necrosis of the brain cells and a high risk of pituitary 
dysfunction. Radiotherapy is frequently ineffective and 
thus the search for other therapeutic options has been 
carried out [10, 12]. Our experience with TMZ treatment 
comes from the studies on glioblastoma multiforme, 
followed by the first use of the medication in aggressive 
pituitary tumours in 2006 [13, 14]. These reports were 
quickly followed by a number of case reports and a few 
studies on a series of patients. According to a review 
by Halevy and Whitelaw published in 2017, the overall 
response rate was 45% with a further 27% reporting 
stable disease [4]. In a series of 24 patients, Bengtsson 
et al. reported a 46% response to the treatment: three 
patients having undergone a complete response, nine 
complete tumour regression, and in eight patients 
a partial regression was observed [15]. TMZ therapy 
resulted in stabilising the disease (total remission, 
partial remission, or lack of progression) in more than 
60% of patients [4, 15–17]. Clinically functional tumours 
responded better than non-functioning ones, with up to 
a 50% response rate in prolactinomas and corticotroph 
tumours [4, 15–17]. The results of the studies might be 
related to publication bias. The published studies are 
difficult to compare due to different durations of treat-
ment, follow-up, and different protocols used. There is 
also a probability of reporting mostly positive results, 
or results with short follow-up. According to Halevy et 
al., the response is usually seen within three cycles [4]. 
An absence of response after three cycles might predict 
resistance to the treatment, as suggested by Raverot et 
al. [4, 7]. The mean treatment duration in published 
series was 9–12 months [4]. Our patient, similarly to 
other cases with corticotropinoma aggressive tumours, 
had rapid tumour progression after transsphenoidal 
neurosurgeries, all non-radical due to the size of the tu-
mour and invasive growth with infiltration of the clivus, 
suprasellar region, cavernous sinus, carotid arteries, and 
optic chiasm. Also, repeated bilateral adrenalectomy 
was not radical, performed as ‘life saving’ in the course 
of severe hypocortisolism. Stereotactic radiotherapy 
and gamma knife surgery were also ineffective. We 
observed clinical and biochemical response after TMZ 
implementation from the third course up to the 7–8th 
course of therapy with stabilised tumour size assessed 
after the third cycle. However, clinical symptoms of 
tumour mass effect like headaches, visual field impair-
ment, and finally hearing loss started to progress from 
the 7–8th cycle. A similar case of invasive corticotroph 
adenoma (Crooke’s cell corticotropinoma with MIB-1 
index < 1) resistant to standard therapy treated with 
temozolomide was described by Kurowska et al. in 
2016 [18]. In that case the authors achieved long-term 
(33-month) complete remission after TMZ treatment 
[18]. After six courses of standard TMZ therapy tumour 
regression was observed, and nine courses resulted in 
a total radiological tumour shrinkage and hormonal 
normalisation [18]. In another case of invasive cortico-
troph adenoma (a patient with Nelson Syndrome after 
bilateral adrenalectomy) resistant to standard therapy 
treated with TMZ, tumour volume reduction was about 
20% after three cycles with TMZ with a decrease in 
ACTH level [19]. The patient received nine cycles of 
TMZ without the progression of the disease and with 
a stable volume of the tumour. However, after TMZ 
withdrawal and remission during a six-month follow-
up tumour progression was observed [19].
Significant tumour shrinkage with decreased 
hormone secretion was also reported by Raverot et 
al. in two of five patients with pituitary carcinoma 
(one with ACTH- and another with PRL-secreting 
carcinoma) [7]. Moyes et al. presented a case of a pa-
tient with an aggressive corticotroph adenoma with 
significant clinical improvement, reduction of serum 
plasma ACTH from 2472 to 389 pmol/L (about 84%), 
and regression of tumour in NMR after four cycles of 
TMZ treatment [20]. Curto et al. also described a case 
report of a patient with an ACTH-secreting carcinoma, 
in whom TMZ therapy induced dramatic tumour size 
reduction (> 90%) [21]. 
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There are also suggested biochemical markers of 
TMZ responsiveness that were not analysed in our 
case. O6-methyl-guanine-DNA methyltransferase 
(MGMT) is a DNA repair protein that reverses alkyla-
tion at the O6 position of guanine by transferring the 
alkyl group to a sulphur group of cysteine, removing 
the alkylating adducts induced by TMZ treatment, and 
providing resistance to TMZ. The effectiveness of TMZ 
is suggested to be related to the down-expression of 
O6-methylguanine-DNA methyltransferase (MGMT) [22].
According to Lau et al. [23] and others, high MGMT 
expression is suggestive of a lack of response to TMZ. 
DNA mismatch repair protein (MSH6) also corre-
lated with the responses of atypical pituitary adenomas 
and pituitary carcinomas to temozolomide. In a Japa-
nese study Hirohata T et al. [24] showed that preserving 
MSH6 function was contributory to the effectiveness of 
TMZ in malignant pituitary neoplasms.
Side effects
Temozolomide (TMZ) is characterised by good toler-
ability and low toxicity. Most information regarding 
side effects comes from experience in the treatment 
of gliomas. The most common adverse effects of TMZ 
were quoted in the description made by the producer 
of TMZ. They are the following: fatigue, nausea/vom-
iting, headache, constipation, anorexia, hemiparesis, 
diarrhoea, fever, dizziness, viral infection, amnesia, 
insomnia, and haematological disorders. There is also 
evidence, although limited, of the side effects of TMZ in 
aggressive pituitary tumours. According to Bengtsson 
et al., in a series of 24 patients with aggressive pituitary 
tumours, adverse effects were reported in 54% cases, 
with most being mild [21]. Fatigue is the most com-
mon side effect of TMZ therapy (60% of patients) [25, 
26], followed by myelosuppression (31%) and nausea/ 
/vomiting [26, 27]. In our case, we did not observe 
typical side effects of TMZ, but hearing loss started to 
progress from the eighth cycle. According to Zachary et 
al., in a cohort of seven patients treated with TMZ for 
aggressive pituitary tumours, in one case progressive 
bilateral sensorineural hearing loss was observed. The 
authors claimed that they had not seen hearing loss in a 
large group of patients with malignant gliomas treated 
with TMZ in their centre, but they could not exclude 
TMZ as the causative agent in this case [28]. In our case, 
an MRI examination revealed massive invasion of the 
inner ear with compression on the right cochlea, which 
could explain the hearing loss. Our patient initially had 
liver steatosis in the course of the disease. During the 
treatment with ketoconazole, a potentially hepatotoxic 
agent, we observed the deterioration of the liver func-
tion. In our case the additional implementation of TMZ 
had no impact on liver function. However, in several 
cases TMZ caused liver function impairment ranging 
from mild to severe [29, 30]. 
We also obtained a full haematological profile at 
day 14 during standard 28-day TMZ dosing cycles. 
Haematological parameters and liver function tests 
were comparable with results before treatment. To 
prevent nausea and vomiting we used ondansetron 
during the five-day chemotherapy course. Our patient 
received prophylactic trimethoprim-sulfamethoxazole 
to prevent the risk of opportunistic infection, particu-
larly Pneumocystis pneumonia (PCP), as suggested by 
Righi et al. [31]. 
Combination therapy and other treatment  
options 
The last treatment we decided to use was a somatostatin 
analogue pasireotide. However, the evidence on the 
effectiveness of pasireotide in aggressive corticotroph 
tumours is very scarce. In a similar case of a patient 
with a large corticotroph tumour, following bilateral 
adrenalectomy, the lowering of ACTH (from 42710 pg/ 
/mL to 4272 pg/mL) and the sustained reduction of the 
suprasellar tumour after one month of therapy were ob-
served, remaining stable over 19 months of follow-up [32]. 
In another eight patients with Nelson’s syndrome, 
pasireotide had minimal effects on tumour volume; 
however, reductions in ACTH levels in most patients 
were observed. In our case, due to the very short dura-
tion of treatment, any conclusions on the treatment with 
pasireotide cannot be drawn. Regarding side effects, we 
observed rapid deterioration of diabetes mellitus after 
implementation of pasireotide.
To improve response rates of TMZ, combination 
treatments have been investigated. In a study with 
capecitabine given before TMZ (CAPTEM) a partial re-
sponse of long duration in four out of four corticotroph 
tumours was observed [33]. In other studies, capecit-
abine had been added to TMZ after TMZ failure, or at 
progression after an initial response to TMZ alone, but 
with no enhanced effect observed [16, 25, 34]. 
Another promising therapeutic option, which is still 
not in use, is peptide receptor radionuclide therapy 
(PPRT) based on the assumption that pituitary uptake 
of 68Ga-DOTATATE or other radiolabelled somatostatin 
analogues has been demonstrated in PET/CT of aggres-
sive pituitary tumours [35, 36].
Conclusions 
The results of the presented case suggest that TMZ 
treatment monotherapy could have only partial re-
sponse in aggressive corticotroph adenoma causing 
Cushing Disease, followed by sudden progression, 
while in the literature review mostly responsive cases 
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were presented, albeit with different durations of re-
sponse. Therefore, further research on the factors of 
responsiveness and on novel methods to extend the 
duration of the effect of TMZ should be carried out. 
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